Barclays PLC Bicycle Therapeutics PLC Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Barclays PLC holds 2,612 shares of BCYC stock, worth $24,944. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,612

Previous 267 878.28%

Holding current value

$24,944

Previous $6,000 516.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$13.81 - $27.5 $32,384 - $64,487	2,345 Added 878.28%	2,612 $37,000
Q3 2024 Nov 15, 2024	BUY	$19.58 - $27.24 $3,583 - $4,984	183 Added 217.86%	267 $6,000
Q1 2024 May 15, 2024	SELL	$16.75 - $26.1 $250,379 - $390,142	-14,948 Reduced 99.44%	84 $2,000
Q4 2023 Feb 15, 2024	BUY	$13.29 - $22.2 $197,542 - $329,980	14,864 Added 8847.62%	15,032 $272,000
Q3 2023 Nov 07, 2023	BUY	$19.9 - $26.25 $1,671 - $2,205	84 Added 100.0%	168 $4,000
Q1 2023 May 04, 2023	BUY	$20.02 - $31.37 $1,681 - $2,635	84 New	84 $2,000
Q2 2022 Aug 12, 2022	SELL	$12.95 - $46.99 $27,570 - $100,041	-2,129 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$40.12 - $59.5 $59,016 - $87,524	-1,471 Reduced 40.86%	2,129 $93,000
Q4 2021 Feb 14, 2022	SELL	$41.7 - $61.14 $105,167 - $154,195	-2,522 Reduced 41.2%	3,600 $219,000
Q3 2021 Nov 09, 2021	BUY	$27.95 - $44.24 $42,539 - $67,333	1,522 Added 33.09%	6,122 $255,000
Q2 2021 Aug 13, 2021	SELL	$27.0 - $32.28 $429,300 - $513,252	-15,900 Reduced 77.56%	4,600 $140,000
Q1 2021 May 13, 2021	BUY	$19.12 - $30.25 $391,960 - $620,125	20,500 New	20,500 $612,000

Others Institutions Holding BCYC

# of Institutions

104

Shares Held

42.9M

Call Options Held

12.1K

Put Options Held

17.4K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $283M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account